Patent: 9,988,437
✉ Email this page to a colleague
Summary for Patent: 9,988,437
Title: | Anti-human Respiratory Syncytial Virus (RSV) antibodies and methods of use |
Abstract: | Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided. |
Inventor(s): | Williamson; Robert Anthony (London, GB), Wadia; Jehangir (San Diego, CA), Pascual; Gabriel (San Diego, CA), Keogh; Elissa (San Diego, CA) |
Assignee: | Janssen Vaccines & Prevention B.V. (Leiden, NL) |
Application Number: | 15/077,558 |
Patent Claims: | see list of patent claims |
Details for Patent 9,988,437
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 06/19/1998 | ⤷ Try a Trial | 2029-08-13 |
Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | Injection | 103770 | 07/23/2004 | ⤷ Try a Trial | 2029-08-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |